Afimmune's Epeleuton shows large decreases in viral load and pathological changes in COVID-19 study
Afimmune, a clinical stage drug discovery company focused on the development of biologically active lipids for the treatment of inflammatory and cardiometabolic diseases, today announced key findings with Epeleuton in a well-established hamster model for SARS-CoV-2 infection. Epeleuton has already been shown to have anti-inflammatory and positive metabolic effects in clinical trials in patients (phase 2) conducted by the Company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210826005039/en/
Dr. John Climax, Chairman and CEO of Afimmune (Photo: Business Wire)
Epeleuton at clinically relevant doses decreased viral load and replication as evidenced by significant and dose-dependent decreases of viral titres and SARS-CoV-2 RNA in throats, nasal turbinates and lungs. At the higher Epeleuton dose, as early as day 1 and on the peak of viral load on day 2, there were no detectable viral titres in the throat.
Epeleuton also decreased the extent and severity of inflammatory and histopathological changes in both the upper and lower respiratory tracts in a dose-dependent manner.
“As concerns about development of resistance to monoclonal antibodies grow, access to a variety of treatment approaches becomes more important. These data suggest complete respiratory tract coverage and indicates the therapeutic potential of Epeleuton as a safe and effective oral outpatient treatment for COVID-19,” said Dr. John Climax, CEO of Afimmune.
Commenting further on the results, Dr. John Climax said: “These preclinical data suggests that Epeleuton has potential to reduce COVID-19 disease burden and risk of hospitalisation due to the dual action of the direct antiviral effects against SARS-CoV-2 and the already proven anti-inflammatory outcomes. The potency of Epeleuton on viral load, replication, and histopathological improvement on both the upper and lower respiratory tract underline the therapeutic potential of Epeleuton in COVID-19 and possibly in long COVID. These unique findings will soon be published. Discussions are ongoing with regulatory agencies and potential partners so that the Company can quickly commence further clinical trials with Epeleuton, a much-needed treatment option for COVID-19.”
About Epeleuton
Epeleuton, previously named DS102, is 15-hydroxy eicosapentaenoic acid (15(S)-HEPE) ethyl ester, a derivative of an endogenous downstream metabolite of EPA. Epeleuton is a new chemical entity.
Epeleuton's cardiometabolic and anti-inflammatory data (phase 2) has been published in the peer-reviewed Journal of the American Heart Association (JAHA). The paper can be found here.
Epeleuton is also currently being investigated in TRIAGE (ClinicalTrials.gov Identifier: NCT04365400), a randomised, double-blind, placebo-controlled, dose finding phase 2b study which is being conducted in Europe and the United States to assess the efficacy and safety of orally administered Epeleuton patients with hypertriglyceridemia and type 2 diabetes. Patients will receive either Epeleuton or placebo for 26 weeks. The primary outcomes will be percentage change in triglycerides from baseline to week 16 and change in HbA1c from baseline to week 26. Results are expected around Q3 2022.
About Afimmune
Afimmune is a clinical stage drug discovery and development company developing biologically active lipids for the treatment of metabolic disorders, such as dyslipidemia, type 2 diabetes, cardiovascular disease in addition to COVID-19 and non-alcoholic steatohepatitis (NASH). The company is headquartered in Dublin, Ireland. For more information, visit www.afimmune.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210826005039/en/
Contact information
Afimmune
investor.relations@afimmune.com
Halsin Partners
Mike Sinclair
+44 7968 022075
msinclair@halsin.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo